Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
72.87
-0.95 (-1.29%)
Jun 16, 2026, 4:00 PM EDT - Market closed
Sol-Gel Technologies Revenue
Sol-Gel Technologies had revenue of $108.00K in the quarter ending March 31, 2026, a decrease of -89.52%. This brings the company's revenue in the last twelve months to $18.47M, down -20.93% year-over-year. In the year 2025, Sol-Gel Technologies had annual revenue of $19.39M with 68.04% growth.
Revenue (ttm)
$18.47M
Revenue Growth
-20.93%
P/S Ratio
12.90
Revenue / Employee
$659,464
Employees
28
Market Cap
238.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.39M | 7.85M | 68.04% |
| Dec 31, 2024 | 11.54M | 9.98M | 642.47% |
| Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
| Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
| Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
| Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
| Dec 31, 2019 | 22.90M | 22.78M | 17,655.04% |
| Dec 31, 2018 | 129.00K | -45.00K | -25.86% |
| Dec 31, 2017 | 174.00K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 75.11M |
| Orchestra BioMed Holdings | 32.72M |
| Foghorn Therapeutics | 28.22M |
| Adagene | 7.67M |
| Fate Therapeutics | 6.32M |
| Entrada Therapeutics | 5.74M |
| Humacyte | 2.02M |
| YD Bio | 510.36K |
SLGL News
- 18 days ago - Sol-Gel Technologies initiated with a Buy at TD Cowen - TheFly
- 19 days ago - Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year - TheFly
- 19 days ago - Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 19 days ago - Sol-Gel Technologies Earnings release: Q1 2026 - Filings
- 3 months ago - Sol-Gel Technologies 459K share Spot Secondary priced at $72.00 - TheFly
- 3 months ago - Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering - GlobeNewsWire
- 3 months ago - Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025 - GlobeNewsWire
- 3 months ago - Sol-Gel Technologies Annual report: Q4 2025 - Filings